NCT00722631View on ClinicalTrials.gov

Anti-Inflammatory Effects of Pioglitazone

NACompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2012

Conditions
Impaired Glucose ToleranceType 2 Diabetes MellitusAtherosclerosis
Interventions
DRUG

Pioglitazone

Subjects who meet eligibility criteria will be titrated up to a maximum of 30 mg/day pioglitazone.

DRUG

Glimepiride

Subjects who meet eligibility criteria will be titrated up to a maximum of 4 mg/day glimepiride.

Trial Locations (1)

830-0011

Kurume University Hospital, Kurume

All Listed Sponsors
lead

Kurume University

OTHER

NCT00722631 - Anti-Inflammatory Effects of Pioglitazone | Biotech Hunter | Biotech Hunter